Cookies on this site

GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. CRUK recently interviewed CEO, Tiffany Ma, who co-founded the venture while completing her DPhil at the University of Oxford.

Tiffany began her PhD in The Department of Oncology in 2018. GambitBio was launched in 2023 as part of her entry for University of Oxford’s All-Innovate business idea competition.

Speaking to CRUK about the venture, Tiffany said: 'GambitBio exists to push for early detection and reduce the number of cancer-related deaths. We want people to be able to detect what is wrong earlier so clinicians can intervene and treat the problem sooner. Early detection can give people up to 95% survival rate over a 10-year period for certain cancer types.'

Read the full interview with Tiffany on the Cancer Research Horizon's website. 

Similar stories

Stronger immune system may help protect against prostate cancer

Higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer, in a new study led by researchers at Oxford Population Health.

Bringing patient and public perspectives into cancer research

We recognise the importance of learning from the experiences of people affected by cancer and ensuring their perspectives help inform cancer research. In 2026, we hosted two successful Patient and Public Involvement (PPI) forums, bringing together researchers and PPI representatives to explore key questions and identify ways to improve cancer research in Oxford.

Blood proteins could reveal clues to prostate cancer risk more than a decade before diagnosis

Proteins linked to the immune system, cell adhesion and blood vessel formation, as well as proteins linked to known prostate cancer genes, were associated with the risk of developing prostate cancer, including aggressive disease, in a new study led by researchers at Oxford Population Health.